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Summary
Background.  —  Although  primary  angioplasty  achieves  thrombolysis  in  myocardial  infarction
(TIMI) 3  ﬂow  in  most  patients  with  ST-elevation  myocardial  infarction,  epicardial  recanalization
does not  guarantee  optimal  perfusion  in  a  large  proportion  of  patients.  The  inﬂuence  of  mul-
tivessel disease  on  myocardial  reperfusion  and  survival  after  primary  angioplasty  has  not  been
extensively  investigated.
Aim.  —  To  evaluate  the  impact  of  multivessel  disease  on  myocardial  perfusion  and  survival  in  a
large cohort  of  patients  with  ST-elevation  myocardial  infarction  treated  with  angioplasty  and
glycoprotein  (GP)  IIb/IIIa  inhibitors.
Methods.  —  This  analysis  is  based  on  1494  patients  undergoing  primary  angioplasty  included  in
the EGYPT  database.  Myocardial  perfusion  was  evaluated  by  angiography  or  ST-segment  resolu-
tion, whereas  infarct  size  was  estimated  by  using  peak  creatine  kinase-MB  (CK-MB).  Follow-up
data were  collected  between  30  days  and  1  year  after  primary  angioplasty.
Results.  —  Multivessel  disease  was  observed  in  870  patients  (58.2%).  The  extent  of  coronary
artery disease  was  associated  with  age,  diabetes,  hypertension,  previous  myocardial  infarction,
previous revascularization,  abciximab  treatment  and  longer  ischaemic  time,  and  was  indepen-
dently associated  with  impaired  angiographic  myocardial  perfusion  (adjusted  odds  ratio  1.18,
95% conﬁdence  interval  [CI]  1.01—1.40,  P  =  0.049).  At  208  ±  160  days,  the  extent  of  coronary
artery disease  was  independently  associated  with  higher  mortality  (adjusted  hazard  ratio  1.54,
95% CI  1.06—2.24,  P  =  0.022).
Conclusions.  —  Among  patients  with  ST-elevation  myocardial  infarction  undergoing  primary
angioplasty  with  GP  IIb/IIIa  inhibitor  treatment,  the  extent  of  coronary  artery  disease  was
independently  associated  with  impaired  myocardial  perfusion  and  survival.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Justiﬁcation.  —  Bien  que  l’angioplastie  primaire  aboutisse  à  un  ﬂux  TIMI  3  chez  la  majorité  des
patients  ayant  un  infarctus  du  myocarde  avec  sus-décalage  du  segment  ST  (STEMI),  la  recana-
lisation épicardique  ne  garantit  pas  une  reperfusion  optimale  dans  une  proportion  signiﬁcative
de patients.  L’inﬂuence  de  la  présence  de  lésions  coronaires  pluritronculaires  sur  la  reperfusion
myocardique  ainsi  que  la  survie  au  décours  d’une  angioplastie  primaire  n’a  pas  été  évaluée  de
fac¸on détaillée.
Objectifs.  —  Évaluer  l’impact  de  lésions  coronaires  pluritronculaires  sur  la  perfusion
myocardique  et  la  survie  au  sein  d’une  cohorte  de  patients  ayant  un  STEMI  traité  par  angioplastie
primaire  et  sous  anti-GPIIb-IIIa.
Méthode.  —  Cette  analyse  a  inclus  1494  patients  bénéﬁciant  d’une  angioplastie  primaire,  inclus
dans la  base  EGYPT.  La  perfusion  myocardique  a  été  évaluée  angiographiquement  ou  sur  la
résolution  du  sus-décalage  du  segment  ST  et  la  taille  de  l’infarctus  a  été  évaluée  sur  le  pic  de
CPK-MB. Les  données  de  suivi  ont  été  collectées  à  j30  et  à  un  an  après  l’angioplastie  primaire.
Résultats. — Les  lésions  coronaires  pluritronculaires  ont  été  observées  chez  870  patients
(58,2 %).  L’étendue  de  la  maladie  coronaire  était  associée  à  l’âge,  au  diabète,  à  l’hypertension
artérielle,  à  un  antécédent  d’infarctus  du  myocarde,  à  un  antécédent  de  revascularisation  coro-
naire, à  un  traitement  par  abciximab,  et  à  une  durée  prolongée  de  l’ischémie  et  était  associée
de fac¸on  indépendante  à  une  altération  de  la  perfusion  myocardique  évaluée  en  angiographie
(odds ratio  ajusté  1,18,  IC  95  %  1,01—1,4,  p  =  0,049).  À  j208  ±  160,  l’étendue  de  la  maladie
coronaire est  associée  de  fac¸on  indépendante  à  une  surmortalité  (hazard  ratio  ajusté  1,54,  IC
95 %  1,06—2,24,  p  =  0,022).
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Conclusion.  —  Parmi  les  patents  ayant  un  STEMI  traité  par  angioplastie  primaire,  sous  anti-GP
IIb-IIIA, l’étendue  de  la  maladie  coronaire  est  attestée  de  fac¸on  indépendante  à  une  altération
de la  perfusion  myocardique  et  à  la  survie.
© 2013  Elsevier  Masson  SAS.  Tous  droits  réservés.
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In  patients  presenting  with  acute  myocardial  infarction
primary  angioplasty  improves  survival  compared  with  throm-
bolysis,  due  mainly  to  a  large  percentage  of  restoration
of  TIMI  3  ﬂow  [1,2],  with  further  improvement  in  clini-
cal  outcomes  observed  with  the  use  of  new  antithrombotic
therapies  and  devices  [3—10].  However,  epicardial  recanal-
ization  does  not  guarantee  optimal  myocardial  perfusion,
which  remains  suboptimal  in  a  relatively  large  proportion  of
patients  [11,12].  In  addition,  concomitant  atherosclerosis  in
coronary  vessels  other  than  the  infarct-related  artery  (IRA)
is  observed  in  a  notable  proportion  of  patients  undergoing
primary  percutaneous  coronary  intervention  (PCI),  ranging
from  40%  to  50%  [13—17].  The  prognostic  impact  of  multives-
sel  coronary  artery  disease  (CAD)  has  not  been  extensively
investigated  [18—20].  Thus,  the  aim  of  the  current  study
was  to  investigate  the  impact  of  multivessel  disease  on  pro-
cedural  success,  myocardial  reperfusion,  infarct  size  and
mortality  in  patients  with  ST-elevation  myocardial  infarc-
tion  (STEMI)  enrolled  in  Early  Glycoprotein  IIb/IIIa  Inhibitors
in  Primary  Angioplasty  (EGYPT)  database.
Methods
Our  initial  population  comprises  patients  with  STEMI  treated
by  primary  angioplasty  and  included  in  the  EGYPT  database.
Detailed  data  on  the  EGYPT  cooperation  have  been  pub-
lished  [8];  characteristics  of  the  studies  included  are
reported  in  Table  1.  All  patients  were  admitted  within  12  h
of  symptom  onset,  received  aspirin  (500  mg  intravenously)
and  heparin  (10,000  IU  intravenously)  as  well  as  glycopro-
tein  (GP)  IIb/IIIa  inhibitors  before  the  procedure  (in  the
cardiac  care  unit  or  ambulance  [early]  or  in  the  cath  lab
[late]),  and  were  on  double  oral  antiplatelet  therapy  (aspirin
and  clopidogrel)  for  4  weeks  or  more,  after  stent  implan-
tation.  Thereafter,  aspirin  (or  clopidogrel,  in  patients  with
side-effects  from  aspirin)  was  continued  as  monotherapy.
Data  from  angiograms  and  electrocardiograms  were  pro-
vided  by  each  principal  investigator  (not  analysed  by  a
central  core  laboratory).  Analysis  of  angiograms  was  based
on  standard  deﬁnitions  [8].  Angiographic  myocardial  per-
fusion  was  evaluated  by  myocardial  blush  grade  [21]  or
myocardial  perfusion  grade  [22].  Optimal  myocardial  reper-
fusion  was  considered  as  myocardial  blush  grade  3  or
myocardial  perfusion  grade  3.  Distal  embolization  was
deﬁned  as  an  abrupt  ‘cut-off’  in  the  main  vessel  or  one  of  the
coronary  branches  of  the  infarct-related  artery  (IRA),  distal
to  the  angioplasty  site  [8].  Even  though  ST-segment  analy-
sis  was  performed  according  to  the  prespeciﬁed  criteria  of
each  trial,  data  were  provided  according  to  uniform  thresh-
olds  (<  30%  no  resolution;  30—70%  partial  resolution;  >  70%
o
c
d
romplete  resolution).  Infarct  size  was  estimated  using  peak
reatine  kinase  (CK)  and  CK-MB.
Clinical  outcome  was  assessed  between  30  days  and  1
ear  after  primary  angioplasty  by  telephone  interview  or
t  medical  visit.  The  primary  study  outcome  was  mortality
t  follow-up;  the  secondary  study  outcome  was  myocardial
erfusion  as  evaluated  by  myocardial  blush  grade  and  ST-
egment  resolution.
tatistical analysis
tatistical  analysis  was  performed  using  the  SPSS  15.0
tatistical  package.  Continuous  data  are  expressed  as
ean  ±  standard  deviation  (SD)  and  categorical  data  as
ercentage.  The  ANOVA  test  was  used  for  continuous  varia-
les,  and  the  Chi2 test  or  Fisher’s  exact  test  was  used  for
ategorical  variables.  Multiple  logistic  regression  analysis
as  used  to  evaluate  the  impact  of  multivessel  disease  on
mpaired  myocardial  perfusion  after  adjustment  for  signif-
cant  (P  <  0.05)  confounding  baseline  characteristics.  The
ifference  in  event  rates  between  groups  during  the  follow-
p  period  was  assessed  by  the  Kaplan—Meier  method  using
he  log-rank  test.  Cox  regression  analysis  was  used  to  eval-
ate  the  impact  of  multivessel  disease  on  survival  after
djustment  for  signiﬁcant  (P  <  0.05)  confounding  baseline
haracteristics.
esults
he  study  population  comprised  1494  patients  with  STEMI.
ultivessel  disease  was  observed  in  870  patients  (58.2%);
10  patients  had  2-vessel  disease  and  360  patients  with
reater  or  more  than  3-vessel  disease.  Demographic,  clinical
nd  angiographic  characteristics  according  to  the  num-
er  of  diseased  vessels  are  reported  in  Table  1.  The
xtent  of  CAD  was  associated  with  age,  prevalence  of
iabetes,  hypertension,  previous  myocardial  infarction,  pre-
ious  revascularization,  abciximab  treatment  and  longer
schaemic  time,  and  was  inversely  related  to  stent  implan-
ation,  smoking  and  anterior  myocardial  infarction.
As  shown  on  Fig.  1,  the  extent  of  CAD  was  linearly
ssociated  with  impaired  epicardial  reperfusion  (TIMI  0—2
ow)  (odds  ratio  [OR],  1.49,  95%  conﬁdence  interval  [CI]
.21—1.84,  P  <  0.001)  and  myocardial  perfusion  (grade  0—2)
OR  1.23,  95%  CI  1.07—1.43,  P  =  0.005),  even  though  no
ifference  was  observed  in  terms  of  complete  ST-segment
esolution  and  distal  embolization.  The  impact  of  number
f  diseased  vessels  on  impaired  myocardial  perfusion  was
onﬁrmed  after  adjustment  for  confounding  factors  (age,
iabetes,  smoking,  previous  myocardial  infarction,  previous
evascularization,  anterior  myocardial  infarction,  abciximab
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Table  1  Patients’  clinical  and  procedural  characteristics  according  to  Multivessel  Disease.
Variable  I  VD
(n  =  624)
II  VD
(n  =  510)
III  VD
(n =  360)
P  value  (trend)
Clinical
Age  (years)  58.2  ±  12.1  61.6  ±  11.4  64.8  ±  11.9  <  0.001
Female  gender  (%)  23.2  22.0  23.1  0.88
Hypertension  (%) 38.5  45.9  46.9  0.005
Diabetes  (%) 13.5  18.6  22.8  <  0.001
Smoking  (%) 56.3  53.5  43.3  <  0.001
Hypercholesterolemia  (%)  36.2  36.9  38.1  0  57
Previous  myocardial  infarction  (%)  3  10.0  17.2  <  0.001
Anterior  myocardial  infarction  (%)  50.6  42.0  38.2  <  0.001
Previous  revascularization  (%)  4  7.8  14.7  <  0.001
Killip  class  >  1  9.6  14.4  12.7  0.12
Time-to-treatment  (min)  221  ±  130  250  ±  169  272  ±  274  <  0.001
Angiographic
Preprocedural  TIMI  3  ﬂow  19.8  17.4  16  0.12
Coronary  stenting  (%)  85.9  86.6  79.3  0.02
Abciximab  (%)  40.1  32.7  26.4  <  0.001
Early  GP  IIb/IIIa  inhibitors  (%)  51.3  50.0  50.6  0.78
Postprocedural  TIMI  3  ﬂow  (%)  86.9  87.8  96.2  <  0.001
Postprocedural  myocardial  blush  grade  3  (%)  52.2  46.2  42  0.005
Distal  embolization  (%)  10.4  11.2  12.6  0.36
Complete  ST  resolution  56.4  57.9  58.1  0.6
VD: vessel disease; GP: glycoprotein; TIMI: thrombolysis in myocardial infarction.
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Tdministration,  postprocedural  TIMI  3  ﬂow)  (adjusted  OR
.18,  95%  CI  1.01—1.40,  P  =  0.049).
As  shown  on  Fig.  2,  at  208  ±  160  days  of  follow-up  the
xtent  of  CAD  was  associated  with  higher  mortality  (HR
.76,  95%  CI  1.25—2.34,  P  =  0.002),  which  was  conﬁrmed
fter  correction  for  baseline  confounding  factors  (age,  dia-
etes,  smoking,  previous  myocardial  infarction,  previous
evascularization,  anterior  myocardial  infarction,  abciximab
dministration,  postprocedural  TIMI  3  ﬂow  and  myocar-
ial  blush  grade  3)  (adjusted  HR  1.54,  95%  CI  1.06—2.24,
 =  0.022)  (Table  2).  As  shown  on  Fig.  3,  the  presence  of
p
I
p
a
Table  2  Cox  regression  analysis  for  mortality.
Variablea H
Number  of  diseased  vessels  (per  increase  in  number)  1.
Abciximab  treatment  1.
Age  >  75  years  7.
Smoking  1.
Diabetes  2.
Previous  myocardial  infarction 3.
Previous  revascularization 0.
Infarct-related  arteryb 1.
Anterior  myocardial  infarction  2.
Myocardial  blush  grade3 0.
Postprocedural  TIMI  3  ﬂow 0.
TIMI: thrombolysis in myocardial infarction.
a All variables were entered in block in the model.
b Left anterior descending vs non-left anterior descending.ultivessel  disease  did  not  affect  the  beneﬁts  from  early
dministration  of  GP  IIb/IIIa  inhibitor  therapy.
iscussion
he  main  ﬁnding  from  this  study  is  that  among  STEMI
atients  undergoing  primary  angioplasty  who  received  GP
Ib/IIIa  inhibitors  treatment,  multivessel  disease  is  inde-
endently  associated  with  impaired  myocardial  perfusion
nd  mortality.  Even  though  primary  angioplasty  has  demon-
azard  ratio  95%  conﬁdence  interval  P  value
54  1.06, 2.24  0.022
85  0.85, 2.25  0.19
45  3.67, 15.1  <  0.001
75  0.75, 1.87  0.49
04  1.06, 3.94  0.033
02  1.06, 8.63  0.039
65 0.16,  2.62  0.55
18  0.27, 5.14  0.82
94  1.44, 6.00  0.003
46  0.21, 0.98  0.043
45 0.20, 0.96  0.038
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Figure 1. Impact of vessel disease on postprocedural TIMI 3 ﬂow, complete ST-segment resolution (STSR), myocardial blush grade (MBG)
3 and distal embolization.
Figure 2. Kaplan—Meier survival curves showing signiﬁcant
impact of vessel disease on survival.
Figure 3. Kaplan—Meier survival curves showing the outcome of
early and late administration of GP IIb/IIIa inhibitors according to
vessel disease. MVD = multivessel disease; SVD = single vessel dis-
ease.
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trated  improved  survival  compared  with  thrombolysis  in
atients  with  STEMI,  clinical  outcome  remains  unsatisfac-
ory  in  some  subgroups.  Multivessel  disease  is  observed
n  approximately  50%  of  patients  undergoing  primary  PCI
nd  has  been  associated  with  poorer  clinical  outcomes
13—17].  However,  few  studies  have  examined  the  progno-
tic  impact  of  the  angiographic  extent  of  CAD  after  primary
CI,  especially  in  the  contemporary  era  in  which  stents  and
lycoprotein  IIb/IIIa  inhibitors  that  have  become  standard  of
are  [5].
In a  report  from  the  CADILLAC  trial  [23],  Sorajja  et  al.
eported  that  the  presence  of  multivessel  disease  was  a
owerful  independent  predictor  of  mortality,  even  after
djustment  for  differences  in  baseline  clinical  and  angiog-
aphic  variables.  Moreover,  the  negative  prognostic  impact
f  multivessel  disease  was  not  impacted  by  the  use  of  stents
r  glycoprotein  IIb/IIIa  inhibitors.  A  signiﬁcantly  better  out-
ome  was  observed  among  patients  who  received  adjunctive
evascularization  of  the  non-IRA.  In  contrast  to  the  CADILLAC
tudy,  in  our  investigation  all  patients  received  GP  IIb/IIIa
nhibitor  treatment  and  most  were  treated  with  coronary
tenting.  Similarly  to  the  CADILLAC  experience,  we  observed
hat  multivessel  disease  was  independently  associated  with
mpaired  myocardial  perfusion  and  mortality.  Several  fac-
ors  may  in  part  explain  the  worse  outcome  observed
n  patients  with  multivessel  disease.  In  accordance  with
revious  studies,  we  found  that  patients  with  multivessel
isease  have  a  greater  incidence  of  high-risk  baseline  fea-
ures  that  may  contribute  to  an  adverse  prognosis.  Impaired
yocardial  reperfusion  may  additionally  contribute  to  the
orse  outcome.  Several  hypotheses  may  help  to  explain
his  observation,  and  which  certainly  need  further  investi-
ation.  Multivessel  CAD  is  a  marker  of  more  disseminated
therosclerosis,  with  microcirculatory  involvement  in  the
nfarct  vessel,  which  may  directly  diminish  myocardial  per-
usion.  Furthermore,  it  may  reﬂect  a  large  atherosclerotic
urden  in  the  IRA,  which  may  determine  a  greater  amount  of
istal  embolization  and  subsequent  capillary  plugging  [24].
inally,  multivessel  disease  may  be  a  marker  of  endothelial
ysfunction  [25]  or  indicate  greater  systemic  inﬂamma-
ion  [26].  Recent  studies  have  shown  signiﬁcant  mortality
eneﬁts  from  the  use  of  manual  thrombectomy  devices
9,10],  which  should  therefore  be  strongly  considered  in
hese  high-risk  patients  in  order  to  improve  reperfusion  and
urvival.  Despite  its  high  prevalence,  few  data  have  been
eported  so  far  on  the  optimal  management  of  patients  with
cute  myocardial  infarction  and  multivessel  disease.  Reports
egarding  the  need  for  and  timing  of  subsequent  revascu-
arization  of  diseased  vessels  following  acute  myocardial
nfarction  have  been  limited  to  retrospective  analyses  of
urgical  series,  and  have  not  led  to  a  clear  consensus.  A
mall  randomized  trial  was  stopped  prematurely  due  to  slow
ecruitment  [27].  In  a  recent  randomized  trial  [28], 214
onsecutive  patients  with  STEMI  and  multivessel  CAD  under-
oing  primary  angioplasty  were  randomized  before  the  ﬁrst
ngioplasty  to  one  of  three  strategies:
culprit  vessel  angioplasty  only;
staged  revascularization  and;
simultaneous  treatment  of  non-IRAs.
During  a  mean  follow-up  of  2.5  years,  42  (50.0%)  patients
n  the  ‘culprit  vessel  angioplasty  only’  group  experiencedG.  De  Luca  et  al.
t  least  one  major  adverse  cardiac  event,  13  (20.0%)  had
n  event  in  the  staged  revascularization  group,  and  15
23.1%)  in  the  simultaneous  treatment  of  non-IRAs  group
P  <  0.001).  In-hospital  death,  repeat  revascularization  and
ehospitalization  occurred  more  frequently  in  the  culprit
essel  angioplasty  only  group  (all  P  <  0.05),  while  there  was
o  signiﬁcant  difference  in  reinfarction  among  the  three
roups.
A  recent  meta-analysis  of  randomized  and  non-
andomized  trials  showed  safety  and  efﬁcacy  of  a
ultivessel  PCI  approach  compared  with  culprit  vessel
ngioplasty  only,  with  a  signiﬁcant  reduction  in  the  rate
f  revascularizations,  but  no  beneﬁt  in  terms  of  death  and
e-myocardial  infarction  [29].  However,  current  guidelines
ecommend  revascularization  of  non-IRA  stenoses  only  in  the
resence  of  haemodynamic  or  electrical  instability.  Future
arge  randomized  trials,  especially  in  the  era  of  new  gener-
tion  drug-eluting  stents,  are  certainly  needed  to  evaluate
hether  an  aggressive  approach  to  obtain  in-hospital  com-
lete  revascularization  might  impact  on  long-term  survival
mong  STEMI  patients  with  multivessel  disease.
tudy limitations
he  major  limitation  of  the  current  study  is  the  absence  of
 centralized  core-lab,  even  though  angiographic  and  ECG
ata  were  analysed  with  similar  criteria  across  trials.  Enzy-
atic  infarct  size  was  estimated  by  peak  CK  and  CK-MB,
hereas  the  use  of  scintigraphy  techniques  could  potentially
ave  improved  the  results.  The  availability  of  the  GRACE
core  and  data  on  ejection  fraction  would  have  improved
he  quality  of  our  results.  Unfortunately,  these  data  were
ot  collected.  Finally,  data  on  non-target  vessel  revascu-
arization  during  hospitalization  or  at  follow-up  were  not
outinely  collected.
onclusions
his  study  showed  that  among  STEMI  patients  undergoing
rimary  angioplasty  and  on  GP  IIb/IIIa  inhibitor  treat-
ent,  multivessel  disease  is  independently  associated  with
mpaired  myocardial  perfusion  and  survival.  Thus  all  efforts
hould  be  attempted  to  use  adjunctive  mechanical  devices
r  pharmacotherapies  to  improve  perfusion  and  clinical  out-
ome  in  these  high-risk  patients.
isclosure of interest
he  authors  declare  that  they  have  no  conﬂicts  of  interest
oncerning  this  article.
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